Vaccine:
Covid-19 vaccine (Covilo / BBIBP-CorV)

Return to company overview

Sinopharm Vaccine Summary Scorecard

A: Commitments and AccountabilityScoreC: International cooperationScore
A1 The company publishes a global access plan for its productC1 The company commits to C-TAP or MPP
A2 The company commits to comply with human rights standards in relation to product development and marketing C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator
C4 The company agrees to license its Covid-19 medical products to other companies
E: Equality, non-discrimination & equityScoreT: TransparencyScore
E1 The company makes the active ingredient available on reasonable ground. [Only for therapeutics]T1 The company publishes its R&D costs.
E2 The company commits to full technology transfer to other manufacturersT2 The company publishes its profit margin.
E3 The company commits to non-profit, ‘fair’, or differential pricingT3 The company publishes the average and/or marginal costs of production.
E4 The company equitably distributes supplies globally. [Only applies to vaccines]T4 The company publishes its production capacity.
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]T5 The company publishes the public subsidies it received during product development and/or testing.
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable].T6 The company publishes the text of licensing agreements.
T7 The company registers its clinical trials in public repositories.

Sinopharm Vaccine Detailed Evaluation

Explore the results of PAF’s research into Sinopharm’s behaviour. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading). Click on the ‘+’ sign next to each entry to expand and learn more. 

A: Commitments and Accountability

Overall score:

A1 The company publishes a global access plan for its product
  • Liu Jingzhen, Chairman of China National Pharmaceutical Group Co., Ltd on Sep 26 2021, on Sinopharm’s response to the pandemic: rapidly expand production capacity; participate in global distribution mechanisms (doses to COVAX); enhance local production and supply capacity through technology transfer; provide assistance to countries and regions ‘with weak response to the epidemic’ 
  • Score: 
A2 The company commits to comply with human rights standards in relation to product development and marketing
  • Mentions of ‘social responsibility’, but not human rights explicitly
  • Score: 

C: International Cooperation

Overall score:

C1 The company commits to C-TAP or MPP 
  • No evidence of committing to a responsible licensing mechanism
  • Score: 
C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents  
  • China is supportive of vaccine diplomacy and the patent waiver, and Sinopharm is a state-backed enterprise. However, no explicit commitment to not enforce patents.
  • Score: 
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator 
  • Yes, 170M doses donated to COVAX
  • Score: 
C4 The company agrees to license its Covid-19 medical products to other companies 
  • Yes, deals with G42  in the UAE to produce the vaccine under the name Hayat-vax (fill and finish) and with Duopharma Biotech (Malaysia, fill-and-finish site)
  • Score: 

E: Equality, non-discrimination & equity

Overall score:

E1 The company makes the active ingredient available on reasonable ground

[Only relevant for therapeutics]

E2 The company commits to full technology transfer to other manufacturers
  • Limited technology transfer in the form of fill-and-finish sites (see C4)
  • Score: 
E3 The company commits to non-profit or ‘fair’ pricing

  • Prices ranging from 9 USD/dose (Argentina), to 36USD/Dose (Hungary): differential pricing. 1 quarter of what the HIC paid (should be around 1 tenth to be ‘fair’- eg AstraZeneca: non-profit to Argentina was 4USD/dose)

  • Score:
E4 The company equitably distributes supplies globally. [Only applies to vaccines]
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]
  • No information.
  • Score:  
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable]  
  • No information.
  • Score:

T: Transparency

Overall score:

T1 The company publishes its R&D costs 
T2 The company publishes its profit margin 
T3 The company publishes the average and/or marginal costs of production
  • Sinopharm does not publish the average and/or marginal costs of production
  • Score: 
T4 The company publishes its production capacity
T5 The company publishes the public subsidies it received during product development and/or testing
  • Sinopharm is a state-backed pharma company – possibly partly funded by Chinese government; however, no statement to this effect 
  • Score:
T6 The company publishes the text of licensing agreements
  • No licensing agreement texts are published.
  • Score: 
T7 The company registers its clinical trials in public repositories
  • Yes
  • Score: